A close-up view of dynamic biomarkers in the setting of COVID-19: Striking focus on cardiovascular system.
Aysa RezabakhshSeyyed-Reza Sadat-EbrahimiAlireza AlaSeyed Mohammad NabaviMaciej BanachSamad GhaffariPublished in: Journal of cellular and molecular medicine (2021)
Based on the recent reports, cardiovascular events encompass a large portion of the mortality caused by the COVID-19 pandemic, which drawn cardiologists into the management of the admitted ill patients. Given that common laboratory values may provide key insights into the illness caused by the life-threatening SARS-CoV-2 virus, it would be more helpful for screening, clinical management and on-time therapeutic strategies. Commensurate with these issues, this review article aimed to discuss the dynamic changes of the common laboratory parameters during COVID-19 and their association with cardiovascular diseases. Besides, the values that changed in the early stage of the disease were considered and monitored during the recovery process. The time required for returning biomarkers to basal levels was also discussed. Finally, of particular interest, we tended to abridge the latest updates regarding the cardiovascular biomarkers as prognostic and diagnostic criteria to determine the severity of COVID-19.
Keyphrases
- sars cov
- cardiovascular events
- cardiovascular disease
- early stage
- coronavirus disease
- coronary artery disease
- end stage renal disease
- respiratory syndrome coronavirus
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- type diabetes
- patient reported outcomes
- emergency department
- squamous cell carcinoma
- radiation therapy
- patient reported
- metabolic syndrome
- lymph node
- adverse drug
- disease virus